Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?
Turner, Megan C, Rossfeld, Kara, Salama, April K.S, Tyler, Douglas, Beasley, GeorgiaVolume:
18
Language:
english
Journal:
Expert Opinion on Pharmacotherapy
DOI:
10.1080/14656566.2017.1299710
Date:
March, 2017
File:
PDF, 717 KB
english, 2017